Mink therapeutics announces patients dosed with agent-797 inkt cell therapy in solid tumor cancers

New york, march 03, 2022 (globe newswire) -- mink therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced that it has begun dosing patients with solid tumor cancers with agent-797 alone and in combination with approved anti-pd-1 checkpoint inhibitors in a phase 1 open-label clinical trial.
INKT Ratings Summary
INKT Quant Ranking